Technology & Software Global On demand · 24-48h

Global Ex Vivo Organ Perfusion Technology Market Strategic Research Report

Name: Global Ex Vivo Organ Perfusion Technology Market Strategic Research Report
Brand: Market Research Reports, Inc.
Price: 3500 USD
Availability: PreOrder

Global Ex Vivo Organ Perfusion Technology Market Strategic R…

$3,500 USD

Strategic Research Report

Global Ex Vivo Organ Perfusion Technology Market

$0B2024

0%CAGR

2032Forecast

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: Heart Perfusion, Liver Perfusion, Kidney Perfusion, Lung Perfusion

By Application: Organ Transplant Specialist Hospitals, Organ Banks, Pharmaceutical Research Organizations

Key Players: TransMedics, Lung Bioengineering, OrganOx, XVIVO, TNO, UHN, SCREEN, Bridge to Life, Organ Recovery Systems, Penn Medicine, Johns Hopkins Medicine

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2024 · forecast to 2032

Length: 119 pages

概述

Scope of the Report

The global Ex Vivo Organ Perfusion Technology market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Ex vivo organ perfusion technology involves the process of preserving and maintaining organs outside of the body in a functioning state by continuously perfusing them with a specialized solution. This technology allows for the assessment, preservation, and even treatment of organs before transplantation. During ex vivo organ perfusion, the organ is connected to a perfusion system that delivers oxygenated blood or a preservation solution containing nutrients and medications to maintain cellular viability and function. This method enables the evaluation of organ quality, assessment of viability, and potential repair or treatment of organs that may not be suitable for transplantation using traditional methods. Ex vivo organ perfusion technology has the potential to increase the number of viable organs available for transplantation, improve transplant outcomes, and advance research in organ preservation and regeneration.

This report presents a comprehensive overview of the global Ex Vivo Organ Perfusion Technology market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

Heart Perfusion
Liver Perfusion
Kidney Perfusion
Lung Perfusion

Segment by Application

Organ Transplant Specialist Hospitals
Organ Banks
Pharmaceutical Research Organizations

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Ex Vivo Organ Perfusion Technology market:

Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
Distributors, channel partners and end users in Organ Transplant Specialist Hospitals, Organ Banks, Pharmaceutical Research Organizations evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Segments covered in this report

By Type

Heart PerfusionLiver PerfusionKidney PerfusionLung Perfusion

By Application

Organ Transplant Specialist HospitalsOrgan BanksPharmaceutical Research Organizations

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Volume Analysis
2.1.4 Segment Outlook by Type
2.1.5 Segment Outlook by Application
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Type

3.1 Market Segmentation by Type
3.1.1 Market by Type Overview
3.1.2 Heart Perfusion
3.1.3 Liver Perfusion
3.1.4 Kidney Perfusion
3.1.5 Lung Perfusion
3.1.6 Volume Analysis

04Market Segmentation by Application

4.1 Market Segmentation by Application
4.1.1 Market by Application Overview
4.1.2 Organ Transplant Specialist Hospitals
4.1.3 Organ Banks
4.1.4 Pharmaceutical Research Organizations
4.1.5 Volume Analysis

05Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

06Country-Level Market Forecast

6.1 Asia Pacific
6.1.1 Rest of Asia Pacific
6.2 North America
6.2.1 Rest of North America
6.3 Europe
6.3.1 Rest of Europe
6.4 Middle East & Africa
6.4.1 Rest of Middle East & Africa
6.5 Latin America
6.5.1 Rest of Latin America

07Growth Drivers & Inhibitors

7.1 Growth Drivers & Inhibitors
7.1.1 Section Overview
7.1.2 Growth Drivers
7.1.3 Growth Inhibitors
7.1.4 Driver and Inhibitor Impact Assessment
7.1.5 Analyst Perspective

08Key Company Profiles

8.1 TransMedics
8.1.1 Company Overview
8.1.2 Key Products & Segments
8.1.3 Financial Performance (2023–2025)
8.1.4 Business Strategy
8.1.5 SWOT Analysis
8.1.6 Strategic Implications (2026–2032)
8.2 Lung Bioengineering
8.2.1 Company Overview
8.2.2 Key Products & Segments
8.2.3 Financial Performance (2023–2025)
8.2.4 Business Strategy
8.2.5 SWOT Analysis
8.2.6 Strategic Implications (2026–2032)
8.3 OrganOx
8.3.1 Company Overview
8.3.2 Key Products & Segments
8.3.3 Financial Performance (2023–2025)
8.3.4 Business Strategy
8.3.5 SWOT Analysis
8.3.6 Strategic Implications (2026–2032)
8.4 XVIVO
8.4.1 Company Overview
8.4.2 Key Products & Segments
8.4.3 Financial Performance (2023–2025)
8.4.4 Business Strategy
8.4.5 SWOT Analysis
8.4.6 Strategic Implications (2026–2032)
8.5 TNO
8.5.1 Company Overview
8.5.2 Key Products & Segments
8.5.3 Financial Performance (2023–2025)
8.5.4 Business Strategy
8.5.5 SWOT Analysis
8.5.6 Strategic Implications (2026–2032)
8.6 UHN
8.6.1 Company Overview
8.6.2 Key Products & Segments
8.6.3 Financial Performance (2023–2025)
8.6.4 Business Strategy
8.6.5 SWOT Analysis
8.6.6 Strategic Implications (2026–2032)
8.7 SCREEN
8.7.1 Company Overview
8.7.2 Key Products & Segments
8.7.3 Financial Performance (2023–2025)
8.7.4 Business Strategy
8.7.5 SWOT Analysis
8.7.6 Strategic Implications (2026–2032)
8.8 Bridge to Life
8.8.1 Company Overview
8.8.2 Key Products & Segments
8.8.3 Financial Performance (2023–2025)
8.8.4 Business Strategy
8.8.5 SWOT Analysis
8.8.6 Strategic Implications (2026–2032)
8.9 Organ Recovery Systems
8.9.1 Company Overview
8.9.2 Key Products & Segments
8.9.3 Financial Performance (2023–2025)
8.9.4 Business Strategy
8.9.5 SWOT Analysis
8.9.6 Strategic Implications (2026–2032)
8.10 Penn Medicine
8.10.1 Company Overview
8.10.2 Key Products & Segments
8.10.3 Financial Performance (2023–2025)
8.10.4 Business Strategy
8.10.5 SWOT Analysis
8.10.6 Strategic Implications (2026–2032)
8.11 Johns Hopkins Medicine
8.11.1 Company Overview
8.11.2 Key Products & Segments
8.11.3 Financial Performance (2023–2025)
8.11.4 Business Strategy
8.11.5 SWOT Analysis
8.11.6 Strategic Implications (2026–2032)

09Competitive Landscape

9.1 Competitive Landscape Overview
9.2 Competitive Intensity Assessment
9.3 Key Player Strategies & Positioning
9.4 Competitive Dynamics & Strategic Outlook
9.4.1 Emerging Competitive Threats
9.4.2 Consolidation vs. Fragmentation Outlook
9.4.3 Competitive Response Matrix
9.4.4 Strategic Recommendations, 2026–2032

10Porter's Five Forces Analysis

10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry

11PESTLE Analysis

11.1 Political
11.2 Economic
11.3 Social and Demographic
11.4 Technological
11.5 Legal and Regulatory
11.6 Environmental
11.7 Strategic Implications of the PESTLE Assessment

12SWOT Analysis

13Future Trends & Outlook

13.1 Future Trends & Outlook
13.1.1 Trend Summary and Commercial Maturity Assessment
13.1.2 Technology and Innovation Trends
13.1.3 Long-Term Market Outlook
13.1.4 Investment & M&A Activity Outlook
13.1.5 Overall Outlook Assessment

Frequently asked questions

What does the Ex Vivo Organ Perfusion Technology market cover?

What are the main segments of the Ex Vivo Organ Perfusion Technology market by type?

By type, the market is segmented into Heart Perfusion, Liver Perfusion, Kidney Perfusion and Lung Perfusion.

Which applications drive demand in the Ex Vivo Organ Perfusion Technology market?

Key applications covered include Organ Transplant Specialist Hospitals, Organ Banks and Pharmaceutical Research Organizations.

Who are the key players in the Ex Vivo Organ Perfusion Technology market?

Key players profiled include TransMedics, Lung Bioengineering, OrganOx, XVIVO, TNO, UHN, SCREEN and Bridge to Life, among 11 companies covered in total.

Which regions and countries are covered for Ex Vivo Organ Perfusion Technology?

The market is analysed across Other regions, with 4 country-level markets including Japan and South Korea.

Who should buy the Ex Vivo Organ Perfusion Technology market report?

The report is intended for manufacturers and solution providers, distributors and end users in Organ Transplant Specialist Hospitals, Organ Banks and Pharmaceutical Research Organizations, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Ex Vivo Organ Perfusion Technology market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.